Johns Hopkins researchers reported in Science Advances that targeted biodegradable polymer nanoparticles encoding anti‑CD19 CAR mRNA can program a patient’s T cells in vivo to express CARs and deplete B cells in mice. The simplified nanoparticle approach aims to sidestep complex ex‑vivo CAR‑T manufacturing and reduce cost and logistical barriers to adoptive cell therapy. Complementing that work, teams unveiled an in vivo assay to quantify lipid nanoparticle (LNP) endosomal escape and delivery efficiency—an acknowledged bottleneck for mRNA and gene‑editing therapeutics. Together, these advances attack both the biological payload (CAR mRNA) and a core delivery metric, moving in‑body cell engineering closer to clinical translation.